Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

Illumina, Inc.

Filed: Jun 16, 2026CIK: 0001110803
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Illumina appointed Daniel M. Skovronsky, M.D., Ph.D. as a new independent director, expanding the Board from nine to ten members effective immediately. This governance enhancement reflects the company's commitment to strategic oversight and board composition.

Key Takeaways

Board size increased from 9 to 10 members with immediate appointment of Dr. Daniel M. Skovronsky

Dr. Skovronsky qualifies as an independent director under applicable regulations with no conflicting transactions

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJun 16, 2026
Item5.02
CategoryExecutive Change
CIK0001110803
Accession #ilmn-20260616
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
board change

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings